Form 8-K - Current report:
SEC Accession No. 0001193125-25-154170
Filing Date
2025-07-02
Accepted
2025-07-01 19:15:36
Documents
15
Period of Report
2025-06-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d68389d8k.htm   iXBRL 8-K 30010
2 EX-10.1 d68389dex101.htm EX-10.1 45545
3 EX-99.1 d68389dex991.htm EX-99.1 7238
7 GRAPHIC g68389g0702025844825.jpg GRAPHIC 3765
  Complete submission text file 0001193125-25-154170.txt   214713

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apto-20250624.xsd EX-101.SCH 2855
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apto-20250624_lab.xml EX-101.LAB 17430
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apto-20250624_pre.xml EX-101.PRE 10878
17 EXTRACTED XBRL INSTANCE DOCUMENT d68389d8k_htm.xml XML 3533
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 251097928
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)